2016-03-08T00:00:00.000-05:00
clinical-stage biotechnology company,0.477083
oncology product candidates,0.307832
product candidates,0.307832
non-refundable payments,-0.397546
Conference ID number,0.399976
proof-of-concept study,-0.400806
collaborations,-0.451914
Rigel,-0.0625637
diluted share,-0.457663
clinical trial,-0.402433
contract revenues,-0.416383
Daiichi Sankyo,0.307832
Phase,-0.0935164
forward-looking statements,-0.496892
Rigel website,0.399976
net loss,-0.444887
continued development,-0.391249
autoimmune hemolytic anemia,-0.40162
quarter,-0.0537037
